Researcher.Life Logo

Naunyn-Schmiedeberg's Archives of Pharmacology : Impact Factor & More

eISSN: 1432-1912pISSN: 0028-1298

Key Metrics

CiteScore
4.4
H-Index
96
SJR
Q2Pharmacology
SNIP
0.79
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Naunyn-Schmiedeberg's Archives of Pharmacology

Naunyn-Schmiedeberg's Archives of Pharmacology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher SPRINGER
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1873
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Naunyn-Schmiedeberg's Archives of Pharmacology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Naunyn-Schmiedeberg's Archives of Pharmacology

The effects of sacubitril/valsartan compared to valsartan in experimentally induced chronic kidney disease.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Retraction Note: Pharmacological evaluation of carvacrol anti-migraine potential.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Pharmacological content in the television series "House MD": analysis from a German pharmacologist's perspective.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Retraction Note: Chronic stress-mediated dysregulations in inflammatory, immune and oxidative circuitry impairs the therapeutic response of methotrexate in experimental autoimmune disease models.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Barriers to effective hypertension control in a low-income healthcare setting: The role of therapeutic inertia and its predictors among hypertensive outpatients.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Convallatoxin ameliorates fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis by targeting IDH1.
  • 6 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
The effects of sacubitril/valsartan compared to valsartan in experimentally induced chronic kidney disease.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Retraction Note: Pharmacological evaluation of carvacrol anti-migraine potential.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Pharmacological content in the television series "House MD": analysis from a German pharmacologist's perspective.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Retraction Note: Chronic stress-mediated dysregulations in inflammatory, immune and oxidative circuitry impairs the therapeutic response of methotrexate in experimental autoimmune disease models.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Barriers to effective hypertension control in a low-income healthcare setting: The role of therapeutic inertia and its predictors among hypertensive outpatients.
  • 7 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology
Convallatoxin ameliorates fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis by targeting IDH1.
  • 6 Feb 2026
  • Naunyn-Schmiedeberg's archives of pharmacology

FAQs on Naunyn-Schmiedeberg's Archives of Pharmacology